Journal: Pharmaceuticals
Article Title: Impact of PCSK9 Inhibition on Proinflammatory Cytokines and Matrix Metalloproteinases Release in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque
doi: 10.3390/ph15070802
Figure Lengend Snippet: Differences in concentration of interleukin 18 (IL-18), interleukin 6 (IL-6), tumor necrosis factor α (TNF-α) ( p < 0.001) and metalloproteinase 2 (MMP-2) ( p < 0.05) in the study group before and after treatment.
Article Snippet: Plasma levels of interleukins, cytokines and metalloproteinases were determined using commercially available enzyme immunoassay kits Cloud-Clone Corp., Houston, TX, USA (Human IL-18—SEA064Hu 96, L170622820; MMP-2—SEA100Hu 96, L190730467); and Diaclone, France (Human IL-6 ELISA Kit—950.030.096; Human TNF alfa Elisa Kit—950.090.096); and BioVendor R&D Czech Republic (Human MMP-9—RD191439100CS) respectively.
Techniques: Concentration Assay